Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Egaten in Fascioliasis
NCT04230148Phase 4Completed
- Sponsor
- Novartis
- Start
- Feb 2022
- Primary completion
- Mar 2026
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 5
01
Overview
A Phase 4 trial of triclabendazole in fascioliasis, sponsored by Novartis. Started Feb 2022; status: completed.
02
Drugs
triclabendazole
03
Conditions
fascioliasis
Beyond the preview
Go deeper on NCT04230148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04230148.